Checkpoint Therapeutics, Inc. has announced an update on its planned merger with Sun Pharmaceutical Industries, Inc. The two companies have entered into an amended Agreement and Plan of Merger as of April 14, 2025. According to the terms of the merger, Checkpoint will merge with Snoopy Merger Sub, Inc., a wholly owned subsidiary of Sun Pharma, with Checkpoint continuing as the surviving entity and becoming a wholly owned subsidiary of Sun Pharma. The merger is expected to close on or about May 30, 2025, pending the required stockholder vote and other closing conditions. A special meeting for Checkpoint stockholders to vote on the merger is scheduled for May 28, 2025.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。